Press release content from Accesswire. The AP news staff was not involved in its creation.
Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy
March 5, 2021 GMT
The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients
Lower than expected rate (10.1%) of progression to severe disease or death with no difference between ABX464 and placebo groups
Decision has no impact on ABX464 development in chronic inflammatory indications
ABX464 top-line clinical data expected in Q2 2021 for phase 2b ulcerative colitis trial and phase 2a rheumatoid arthritis trial